First State Bancorporation (First State) is a New Mexico-based bank holding company, which provides a variety of banking services to businesses, individuals, and local governments through its subsidiary bank, First Community Bank, (the Bank). The Bank serves a diverse group of small to medium size businesses, individuals and local governmental entities, and provides conventional commercial loans to established commercial businesses. It offers a range of financial services to the customers, including checking accounts, on-line banking, short and medium term loans, revolving credit facilities, inventory and accounts receivable financing, equipment financing, residential and commercial construction lending, residential mortgage loans, various savings programs, installment and personal loans, and safe deposit services.

Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its combination product candidates targeted for obesity are Contrave which has completed Phase III clinical trials, and Empatic, which has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release (SR) formulation. Bupropion is a prescribed antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. Empatic is a combination of bupropion SR and zonisamide SR. Zonisamide, in a release formulation, was approved in the United States for the adjunctive treatment of partial seizures, a form of epilepsy. These product candidates regulate appetite and energy expenditure through the central nervous system (CNS).

Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahnā€™s pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin, is a inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202.

Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahnā€™s pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin, is a inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202.